L
ipopolysaccharide is the major constituent of the outer cell wall of Gram-negative bacteria and the predominant inducer of inflammatory responses to these bacteria (1, 2) . The recognition of LPS by cells of the innate immune system provides an important first step to identify invading pathogens and to initiate a protective immune response. However, overwhelming inflammation in response to LPS can be harmful and may cause septic shock with organ failure (1, 2) . Therefore, a balanced immune response to pathogens is crucial.
The cellular LPS receptor complex comprises the three molecules CD14, TLR4, and MD-2 (1) . Although TLR4 signals the presence of LPS to the cellular interior, resulting in the production of proinflammatory cytokines and chemokines, the presence of MD-2-that is associated with the extracellular domain of TLR4 -is crucial for the binding of LPS (3) (4) (5) . The interaction between LPS and MD-2 is strongly facilitated in the presence of CD14 (5) . However, the earliest events following the release of LPS require the transfer of LPS to its receptor complex. LPS-binding protein (LBP) 3 acts as a lipid-transfer protein that captures LPS out of aggregates formed by LPS monomers due to its amphiphilic properties and transfers it to CD14 (6 -8) . The spontaneous diffusion of LPS monomers to the cellular-binding site is very slow and transfer by LBP enhances the immune response to LPS up to 1000-fold in vitro (9, 10) . Besides its clear role in facilitating the presentation of LPS to its cellular receptor complex, LBP has also been demonstrated to be involved in the neutralization of LPS via transfer of LPS to lipoproteins such as high-density lipoprotein, low-density lipoprotein, and very low-density lipoprotein (11, 12) . This neutralizing capacity of LBP seems to play a greater role in clinical conditions like sepsis, which are associated with high serum LBP levels (12) . Indeed, addition of high LBP levels or serum from septic patients containing high LBP concentrations has been demonstrated to attenuate the inflammatory response of macrophages and monocytes to LPS in vitro (13, 14) .
Although LBP is constitutively produced by hepatocytes under normal conditions, IL-1␤ and IL-6 synergize in inducing strongly enhanced LBP synthesis during an acute phase reaction (15) . Besides increased LBP serum levels upon systemic infection, elevated LBP levels were also found in bronchoalveolar lavage (BAL) fluid (BALF) during infectious and allergic lung inflammation (9, 16 -18) . Moreover, recent evidence indicates that LBP production is not restricted to hepatocytes and that both lung and intestinal epithelial cells represent additional sources (19 -21) . Synthesis of biologically active LBP by human and murine respiratory epithelial cells was observed upon stimulation with IL-1␤, TNF-␣, and IL-6 (19) . In addition, the inflammatory response of rabbit alveolar macrophages is amplified in the presence of LBP in vitro (9) . Together, these observations indicate a direct and local role for LBP in LPS responsiveness in the respiratory tract and in host defense against Gram-negative pneumonia. Indeed, we and others recently demonstrated that LBP gene-deficient (LBP Ϫ/Ϫ ) mice are highly susceptible to pneumonia caused by Klebsiella pneumoniae (22, 23) suggesting that endogenous LBP contributes to an adequate recognition of Gram-negative bacteria in the lung. In the present study, we sought to determine the role of pulmonary LBP in acute lung inflammation induced by LPS.
Materials and Methods

Mice
Pathogen-free 10-to 12-wk-old female C57BL/6 wild-type mice were purchased from Harlan Sprague Dawley. LBP Ϫ/Ϫ mice were generated as described previously (10) , backcrossed to C57BL/6 background 11 times and bred in the animal facility of the Academic Medical Center (Amsterdam, The Netherlands). Age-and sex-matched mice were used in all experiments. The Animal Care and Use Committee of the University of Amsterdam (Amsterdam, The Netherlands) approved all experiments.
Induction of lung inflammation
Mice were anesthetized by inhalation of isoflurane (Abbott Laboratories), and LPS (from Escherichia coli O55:B5; Sigma-Aldrich) diluted in 50 l of sterile saline was instilled intranasally (i.n.). Control mice received sterile saline. In some experiments, mice received purified human LBP (80 ng; HyCult Biotechnology) i.n. simultaneously with LPS. After 6 or 22 h, mice were anesthetized with Hypnorm (Janssen Pharmaceutical) and midazolam (Roche) and sacrificed by bleeding out the vena cava inferior. Blood was collected in EDTA containing tubes and plasma was stored at Ϫ20°C until further usage.
Bronchoalveolar lavage
The trachea was exposed through a midline incision and cannulated with a sterile 22-gauge Abbocath-T catheter (Abbott Laboratories). Bilateral BAL was performed by instilling two 0.5-ml aliquots of sterile saline. Approximately 0.9 -1 ml of BALF was retrieved per mouse. Total cell numbers were counted from each sample using a hemocytometer (Türck chamber); BALF differential cell counts were done on cytospin preparations stained with Giemsa. BALF supernatant was stored at Ϫ20°C for cytokine and LBP measurements.
Histology
Lungs for histology were harvested at 6 or 22 h after infection, fixed in 10% formalin, and embedded in paraffin. Four-micrometer sections were stained with H&E, and analyzed by a pathologist who was blinded for groups. To quantify lung inflammation and damage, the entire lung surface was semiquantitatively scored as described previously (24) . In brief, the following parameters were analyzed: interstitial inflammation, intra-alveolar inflammation, edema, endothelialitis, bronchitis, pleuritis, and thrombi formation. Each parameter was graded on a scale of 0 -3, with 0: absent, 1: mild, 2: moderate, and 3: severe. The total "lung inflammation score" was expressed as the sum of the scores for each parameter, the maximum being 21.
Assays
Murine LBP was measured using a commercially available ELISA (HyCult Biotechnology) according to the manufacturer's instructions; the detection limit was 0.4 ng/ml. TNF-␣ and KC were measured using specific ELISAs (R&D Systems) according to the manufacturer's instructions. The detection limits were 31 pg/ml for TNF-␣ and 12 pg/ml for KC. Protein levels in BALF were measured using the BCA protein kit according to the manufacturer's instructions (Pierce).
LPS responsiveness of alveolar macrophages
The murine alveolar macrophage cell line MH-S was purchased from American Type Culture Collection and grown in RPMI 1640 (Invitrogen Life Technologies) supplemented with 2 mM L-glutamine, 5 mM HEPES buffer, 10% FCS (unless otherwise indicated), penicillin, streptomycin, and 2-ME. In vitro stimulation was conducted in 96-well plates (Greiner) at a density of 1 ϫ 10 6 cells/ml. Following overnight culture in serum-free medium at 37°C in 5% CO 2 , adherent cells were washed twice in serumfree medium then stimulated overnight with 0.1 ng/ml to 1 g/ml LPS (E. coli O55:B5; Sigma-Aldrich) in the presence or absence of 0.1 ng/ml to 10 g/ml human LBP (HyCult Biotechnology) in serum-free medium. Some experiments were performed in the presence of scavenger receptor A (SR-A) blocking Abs (clone: 2F8; Serotec) at a concentration of 10 g/ml.
Statistical analysis
Serial data were analyzed by one-way ANOVA; differences between two groups were calculated by Mann-Whitney U test. Correlations were calculated by Pearson test. Values are expressed as mean Ϯ SEM. A p value Յ0.05 was considered statistically significant.
Results
LBP is detectable in BALF of healthy mice and rapidly increases in acute lung inflammation
To investigate whether pulmonary LBP is detectable in normal BALF and whether acute lung inflammation induces local release of this protein, we measured LBP in BALF of wild-type mice before and 6 h after i.n. administration of 10 g of LPS or NaCl. Low levels of alveolar LBP were readily detectable in normal mice and LPS induced a significant rise in LBP concentrations (Table I) . Plasma LBP levels, which are known to be 100-fold higher, were unaffected by pulmonary inflammation (Table I ) and no LBP was detectable in LBP Ϫ/Ϫ mice. Hence, i.n. administration of LPS induced a rapid increase in alveolar LBP levels, supporting the notion of locally produced LBP in vivo.
Lung inflammation induced by high dose LPS is enhanced in the absence of LBP
To determine the specific contribution of pulmonary LBP to acute lung inflammation, we i.n. inoculated wild-type and LBP Ϫ/Ϫ mice with 10 g of LPS or saline. LPS induced a strong cell influx that predominantly was caused by polymorphonuclear cells (PMNs) ( p Ͻ 0.05 LPS-treated wild-type vs saline-treated wild-type mice). Surprisingly, the comparison of wild-type and LBP Ϫ/Ϫ mice revealed significantly more PMNs as well as higher TNF-␣ and KC concentrations in BALF of LBP Ϫ/Ϫ mice ( Fig. 1) . Hence, these data suggested that pulmonary LBP inhibits lung inflammation induced by 10 g of LPS in vivo.
FIGURE 1. LBP
Ϫ/Ϫ mice demonstrate enhanced lung inflammation upon i.n. administration of 10 g of LPS. PMN counts, TNF-␣, and KC concentrations in BALF of wild-type (f) and LBP Ϫ/Ϫ mice (Ⅺ) 6 h after i.n. administration of 10 g of LPS (n ϭ 6 per strain). Data are mean Ϯ SEM; ‫,ء‬ p Ͻ 0.05 vs wild-type mice. 
The influence of LBP on LPS-induced pulmonary inflammation depends on the dose of LPS
This surprising finding of a more pronounced pulmonary inflammation in LBP Ϫ/Ϫ mice following LPS challenge led us to investigate whether this observation was attributable to the LPS dose. We therefore repeated these in vivo studies with increasing, though lower, LPS doses. Wild-type and LBP Ϫ/Ϫ mice were inoculated with 1, 10, or 100 ng of LPS i.n. 6 h before BAL was performed, and cell influx and TNF-␣ and KC responses were evaluated. In mice that received the lowest LPS dose (1 ng), an LBP-dependent increase of pulmonary inflammation was found: 1 ng of LPS induced a significantly higher PMN influx and slightly higher BALF TNF-␣ levels in wild-type than LBP (Figs. 2 and 3) . Together, the acute pulmonary inflammation induced by LPS doses as low as 1 ng was augmented in the presence of LBP whereas cell influx and cytokine/chemokine production following higher LPS doses (Ն10 ng LPS) were independent from or even inhibited by the presence of LBP.
To evaluate these findings over a longer period of time, we repeated the in vivo experiments and assessed pulmonary inflammation in response to different LPS doses (1, 10, and 100 ng) after 22 h. At this late time point, cytokines or chemokines could not be detected anymore in most of the BALF samples. A small amount of TNF-␣ (65 Ϯ 12 pg/ml) was detected in BALF of LBP Ϫ/Ϫ mice challenged with 100 ng of LPS. As shown in Fig. 3 , all wild-type mice showed a trend toward resolution of the inflammation in terms of a reduction in alveolar PMN counts (as compared with t ϭ 6 h) at this later time point. In contrast, alveolar PMN counts continued to be elevated (10 ng of LPS) or increased even further (100 ng of LPS) in LBP Ϫ/Ϫ mice. To obtain further proof for enhanced lung inflammation in LBP Ϫ/Ϫ mice after i.n. administration of 100 ng of LPS, histological analysis of lung slides obtained 6 and 22 h postchallenge were performed. Using the semiquantitative scoring system described in Materials and Methods, we could confirm our findings of enhanced and prolonged pulmonary inflammation in LBP Ϫ/Ϫ mice that received 100 ng of LPS i.n. As shown on representative slides in Fig. 4 , the extent of lung inflammation was more severe in LBP Ϫ/Ϫ mice when compared with their wild-type counterparts (lung inflammation score at t ϭ 6 h: wild-type: 7.4 Ϯ 1. This experiment confirms our previous finding of an exaggerated pulmonary inflammation in the absence of LBP and illustrates furthermore that LBP is involved in the timely resolution of pulmonary inflammation.
Pulmonary LBP concentrations rise in an LPS dose-dependent manner
In Table I , we show elevated LBP protein concentrations within the alveolar compartment following LPS challenge. To study whether this increase in LBP concentrations correlates to the dose of LPS administered, we measured LBP levels in BALF of mice treated with increasing LPS doses (1, 10, or 100 ng). Although in wild-type mice, 1 ng of LPS did not induce any change in LBP levels, a dose-dependent rise in alveolar LBP could be revealed in response to higher LPS doses (Ն10 ng LPS) (Fig. 5A) . To exclude the possibility that this increase in alveolar LBP levels is a result of extravasated serum proteins, we compared LBP levels with total BALF protein concentrations in BALF of wild-type mice (Fig.  5B) : while LBP concentrations increased in a LPS-dose dependent manner (Pearson correlation LPS dose vs LBP concentration: r ϭ 0.79, p ϭ 0.003), protein levels remained essentially unaltered and no correlation was found between LBP and total protein concentrations in BALF of wild-type mice (Pearson correlation LBP concentration vs total protein concentrations: r ϭ 0.39, p ϭ 0.14). As expected, LBP could not be detected in BALF or plasma of LBP Ϫ/Ϫ mice whereas in these animals total alveolar protein concentrations increased in response to LPS and correlated with PMN influx (Pearson correlation total protein concentrations vs PMN count: r ϭ 0.79, p ϭ 0.0003) and TNF-␣ levels (Pearson correlation total protein concentrations vs TNF-␣ levels: r ϭ 0.82, p ϭ 0.0001). Together, alveolar LBP (but not total protein) concentrations increased in a LPS-dose-dependent manner in wild-type mice. The increase in alveolar protein concentrations most likely reflects the extent of capillary leakage found during acute lung injury and exclusively correlated with alveolar inflammation parameters as reflected by the high levels measured in LBP Ϫ/Ϫ mice challenged with 100 ng of LPS.
The increased lung inflammation in LBP Ϫ/Ϫ mice induced by high dose LPS is reversed by exogenous LBP
To investigate whether the augmented lung inflammation in LBP Ϫ/Ϫ mice following administration of Ն10 ng of LPS is specifically attributable to the lack of LBP, we administered human LBP in a dose of 80 ng together with 100 ng of LPS to FIGURE 2. Pulmonary LPS responsiveness of LBP Ϫ/Ϫ mice depends on the LPS dose administered. Increasing LPS doses (1, 10, or 100 ng) were administered to wild-type (f) and LBP Ϫ/Ϫ (Ⅺ) mice. After 6 h, TNF-␣ and KC concentrations were assessed in BALF. Data are mean Ϯ SEM of five to six mice per group for each LPS dose. ‫,ء‬ p Ͻ 0.05 vs wild-type mice. both wild-type and LBP Ϫ/Ϫ mice and assessed the inflammatory response. Exogenous LBP did not influence LPS responsiveness in the lungs of wild-type mice (Fig. 6) . In LBP Ϫ/Ϫ mice, however, the administration of LBP in addition to LPS completely reversed the amplified pulmonary inflammation observed in LBP Ϫ/Ϫ mice treated with LPS only. Thus, the coadministration of LBP virtually transformed LBP Ϫ/Ϫ mice to a wild-type phenotype with regard to both PMN influx and alveolar TNF-␣ concentrations, confirming the specificity of the findings.
The LPS responsiveness of alveolar macrophages in vitro depends on LBP
Because we consider the enhanced PMN recruitment a consequence of exaggerated proinflammatory stimuli, we attempted to elucidate the mechanisms involved. In a next step, we therefore examined whether our findings could be reproduced in vitro and whether alveolar macrophages are responsible for our in vivo observations. For this purpose, we stimulated murine alveolar macrophages (MH-S cells) with increasing doses of LPS and LBP in the absence of serum. By doing so, we found a clear LBP and LPS dose-dependent response with respect to TNF-␣ production (Fig.  7A) . Because it has been reported that "supranormal" LBP concentrations can exert inhibitory actions, we also performed stimulations using LBP concentrations up to 10 g/ml (Fig. 7B) . Even 10 g/ml LBP further increased TNF-␣ levels released by alveolar macrophages in vitro. Another major receptor interacting with LPS responsiveness and expressed on alveolar macrophages is SR-A. In an attempt to investigate whether LBP also transfers LPS to SR-A and thereby causes a dampened inflammatory response, we stimulated MH-S cells with LPS and increasing doses of LBP in the presence or absence of a blocking Ab against SR-A. As depicted in Fig. 8 , blockage of SR-A increases the inflammatory response irrespective of LBP. Together, no inhibitory properties of LBP were observed in vitro, indicating either that this observation is not reproducible in vitro or that alveolar macrophages are not the primary target cells for the inhibitory properties of LBP seen in vivo.
Discussion
LBP is an important acute phase protein that has attracted much attention as an enhancer of cellular LPS responsiveness via its unique property to transfer LPS to the CD14/TLR4 receptor complex on immune cells (8) thereby facilitating the inflammatory response to LPS and Gram-negative bacteria in vivo (23, 25, 26) . Additionally, there is evidence suggesting that very high LBP concentrations, such as found in plasma samples of septic patients, inhibit the proinflammatory effects of LPS (13) . Conceivably, the function of LBP depends on diverse aspects, such as concentration, cell types investigated, and-possibly-localization of the stimulus in vivo. The finding of LBP production by respiratory epithelial cells in vitro (19) led us to evaluate the specific in vivo contribution of pulmonary LBP to the inflammatory response induced by LPS. First, we here establish that LPS elicits an increase in alveolar LBP in vivo in a dose-dependent manner, supporting the hypothesis of local, pulmonary LBP production. Second, using LBP Ϫ/Ϫ mice, we were able to demonstrate for the first time that pulmonary LBP-at a naturally occurring low concentration-specifically inhibits and abridges the LPS-induced acute lung inflammation in vivo. These inhibitory properties of pulmonary LBP depended entirely on the LPS-dose administered-with a threshold set at 10 ng of LPS.
While our studies were in progress, Brass et al. (27) reported on the role of endogenous LBP in lung inflammation induced by repeated LPS inhalation during periods up to 4 wk. The authors found reduced cell influx and lower cytokine levels in BALF of LBP Ϫ/Ϫ mice when compared with wild-type mice, indicating that LBP was required for full LPS responsiveness in their model. Of note, the LPS dose administered, albeit repeatedly, was relatively low. Although the precise LPS dose inhaled by an individual mouse is difficult to determine, the approximate LPS concentration in the exposure chambers was determined to be 5 mg of LPS/m 3 air (27) . We also found LBP to promote lung inflammation when a low LPS dose (Ͻ10 ng) was administered. Of crucial importance, higher LPS doses showed quite the opposite, i.e., a diminished inflammatory response in the presence of LBP.
How can this observation be explained? LBP is a transfer protein that binds anionic structures like LPS and shuttles them to respective receptors or other proteins. Because LBP itself is not directly involved in cellular signaling processes, pulmonary LBP likely transfers LPS to other LPS-binding structures (e.g., receptors, lipid-binding molecules, lipoproteins) that neutralize LPS activity. Alternatively, LBP might actively prevent the transfer of LPS to the CD14/TLR4/MD2 receptor that mediates proinflammatory pathways.
Regarding the latter possibility, the CD14/TLR4/MD2 receptor complex prominently features as "the" LPS-signaling structure. As suggested by a recent report, moderate to high LBP levels inhibit the LPS transfer from CD14 to the TLR4/MD-2 signaling receptor in vitro (28) . Thompson et al. (28) showed that LBP removed cell-bound LPS from membrane (m) CD14 and MD-2 resulting in an attenuated inflammatory response. However, the LBP dose required for this to take place was 3 g/ml, which is comparable to plasma levels, but much higher than the concentrations we found in BALF (although LBP levels in the alveolar lining fluid likely are higher considering the dilution caused by the BAL procedure). We studied the interaction of LPS with alveolar macrophages in vitro and found-in accordance with a previous report-a dose-dependent enhancement of the inflammatory response in the presence of LBP (9) . Like Thompson et al. (28) , we added LPS a few minutes before LBP but we were unable to find any LBP-related reduction of the inflammatory response even in the presence of LBP doses as high as 10 g/ml. This in vitro observation is in contrast to the results we found in mice. By stimulating isolated alveolar macrophages of LBP Ϫ/Ϫ and wild-type mice with LPS in vitro, we observed no difference in their capacity to produce TNF-␣, ruling out the possibility of an impaired or exaggerated cytokine secretion of LBP Ϫ/Ϫ macrophages (data not shown). Already, in 1995, Gegner et al. (29) described the potential dual role of LBP and mCD14 in LPS signal enhancement and LPS neutralization. They concluded that LBP is also part of the LPS clearance mechanism and that this pathway bifurcates after binding to mCD14. A more recent publication delineated that TLR4 is responsible for LPS signaling while LPS neutralization is mediated by other receptors in vitro (30) . Using murine blood monocytes and endothelial cells, Dunzendorfer et al. (30) demonstrated that LBP contributes substantially to the neutralization of LPS via transfer to CD14 as well as to other anionic structure binding receptors, presumably SRs. SRs are expressed on macrophages and able to bind anionic ligands including LPS. It is known that SR-A Ϫ/Ϫ mice are hypersensitive to LPS, which might be explained by the fact that SR-A can degrade LPS without concomitant release of proinflammatory cytokines in vitro (31) . However, when blocking SR-A with an Ab, we could not delineate a role for LBP in the enhanced inflammatory response seen with anti-SR-A-treated cells in vitro (Fig. 8) .
Lung epithelial cells have been disclosed to importantly contribute to LPS-induced pulmonary inflammation in vivo via NF-B-activating pathways (32, 33) . Of great interest, lung epithelial cells have also been demonstrated to have the ability to internalize LPS without activation of NF-B (34). Hamann et al. (34) revealed that the internalization and neutralization of LPS by respiratory epithelial cells depended on the presence of LBP (and partly mCD14) in vitro. In an attempt to investigate the potential role for LBP, we measured the internalization of FITC-labeled LPS by respiratory epithelial cells in the presence or absence of LBP. Although we found LPS rapidly internalized by respiratory epithelial cells, we could not identify a role of LBP herein (data not shown). Furthermore, Hamann et al. (34) described that moderate LBP concentrations enhanced the uptake and signaling of LPS by alveolar macrophages, whereas high LBP concentrations (Ն1 g/ml) diminished the inflammatory response in vitro. Stimulations of alveolar macrophages in the presence of up to 10 g/ml LBP did not enable us to reproduce this observation in vitro. However, the major difference between our studies and those by Hamann et al. (34) is the LPS chemotype with which cells were stimulated. While Hamann et al. (34) focused on rough LPS mutants, we made use of smooth LPS. The vast importance of distinct LPS chemotypes has just been highlighted by a recent article disclosing that the TLR4-MD-2 complex is able to differentiate between these LPS chemotypes (35) . Although CD14 is required for MyD88-independent signaling by either LPS chemotype, rough LPS (but not smooth LPS) can bind and signal via the MyD88-dependent pathway in the absence of CD14 (35) . Together, Hamann et al. (34) used rough LPS that also elicits CD14-independent pathways, while our data were generated with CD14-dependent smooth LPS. Our data clearly could not confirm the hypothesis of LBP-mediated neutralization of smooth LPS by respiratory epithelial cells or alveolar macrophages in vitro.
The presence of surfactant proteins (SP) is another unique and specific feature of the pulmonary compartment. SP-A, like LBP, is able to bind anionic structures including rough LPS and to inhibit the inflammatory response of alveolar macrophages to rough or smooth LPS in vitro (36, 37) . Furthermore, SP-A Ϫ/Ϫ mice challenged with intratracheal LPS display increased TNF-␣ and MIP-2 BALF-concentrations when compared with wild-type controls (38) . The potential role of LBP in the SP-A related antiinflammatory mechanisms is controversial. Although Stamme et al. (37) explained the anti-inflammatory properties of SP-A via its capacity to inhibit the binding of rough LPS to LBP, these data could not be confirmed by Alcorn et al. (36) . However, in vivo data thus far only demonstrated the SP-A related decrease in cytokine/ chemokine levels whereas PMN influx was not affected (38) . Nevertheless, the possibility exists that the anti-inflammatory properties of SP-A are masked in mice lacking LBP, which results in higher pulmonary cytokine/chemokine concentrations that indirectly attract more PMNs.
The airways are a site of constant exposure to inhaled pathogens or LPS and it certainly is of crucial importance to fight these pathogens to prevent pneumonia. Conversely, the continuous daily exposure to minute amounts of inhaled LPS might warrant mechanisms that attenuate an excessive inflammatory response that would be detrimental to the host. Our in vivo findings indicate that LBP could be considered an important regulator of the pulmonary immune response: LBP enables the host to respond to small amounts of LPS with a self-limited inflammatory response while contributing to the neutralization of higher LPS doses and thus preventing the harmful consequences of exaggerated lung inflammation. Although premature at this point, therapeutic implications of these findings may prove beneficial in the future.
